Trials / Completed
CompletedNCT01342146
Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children
Efficiency and Safety of Pegylated Somatropin(PEG-somatropin) in the Treatment of Children With Growth Hormone Deficiency: a Multicenter, Randomized, Open-label, Controlled Phase 2 Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the multicenter, randomized, open-label, controlled phase II study is to determine whether pegylated recombinant human growth hormone is effective in the treatment of children with growth hormone deficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegylated Somatropin | 0.1 mg/kg/wk once a week for 25 weeks |
| DRUG | pegylated Somatropin | 0.2 mg/kg/wk once a week for 25 weeks |
| DRUG | Jintropin AQ | 0.25 mg/kg/wk, once a day for 25 weeks |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-01-01
- Completion
- 2007-02-01
- First posted
- 2011-04-27
- Last updated
- 2017-07-31
Source: ClinicalTrials.gov record NCT01342146. Inclusion in this directory is not an endorsement.